ADAKVEO, generically known as crizanlizumab, is a prescription medication designed for the treatment of sickle cell disease in individuals aged 16 years and older. It is a novel therapeutic approach that works by targeting and blocking P-selectin, a cell adhesion molecule that plays a crucial role in the painful vaso-occlusive crises associated with sickle cell disease. By inhibiting P-selectin, ADAKVEO helps to prevent the cells from sticking together and obstructing blood flow, which can lead to severe pain and organ damage in affected individuals. Administered through intravenous infusion, ADAKVEO is part of a new generation of treatments aimed at reducing the frequency of vaso-occlusive crises and improving the quality of life for those living with this chronic condition.